Table 2.

Subject information and clinical evaluations

Sub	Sex	Age	Muscle	SL (μm)	House	Sev	Ash	Zan	PEFF (°)	PESF (°)	AEFF (°)	MyHC gel
AI	M	13	FCU	6.36	1	SS	4	3	-5	-90	-70	x
			ECRB									x
AN	F	12	FCU	4.56	3	SS	3	2B	50	45	-90
			ECRB
AO	F	11	FCU	4.01	5	SM	2	2B	65	60	-50	x
			ECRB									x
AQ	M	15	FCU	4.01	7	M	2	2B	80	80	-50
			ECRB
AT	M	14	FCU	3.57	0	SS	3	3	45	40
			ECRB
BF	F	12	FCU	5.31	6	SM	3	2A	85	85	55	x
			ECRB									x
BP	M	10	FCU	-	-	C	1	0	90	90	90	x
			ECRB
AZ	M	7	FCU	-	-	C	1	0	90	90	90	x
			ECRB									x

Table of the eight subjects used in this study with 2 muscles (FCU and ECRB) per patient with sex and age recorded. Measures of severity were taken to include: intraoperative measurement of sarcomere length (SL) on the FCU, House clinical assessment of activity, Severity (Sev) grouped by House (Severe Severe (SS), Severe Moderate (SM), Mild (M), and Control (C)), Ashworth (Ash) clinical assessment, Zancolli (Zan) classification based on finger extension, passive extension with flexed fingers (PEFF) passive extension with straight fingers (PESF) and active extension with flexed fingers (AEFF). Samples that were available for MyHC SDS-PAGE gels are noted in the final column